^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MI FOLFOXai

    Company:
    Caris Life Sci
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    MI FOLFOXai™ is an Artificial Intelligence-powered predictor of FOLFOX response that utilizes Caris Molecular Intelligence® tumor profiling results. It is intended to be used as an aid in gauging a patient’s likelihood to benefit from FOLFOX chemotherapy (in combination with bevacizumab) as the first-line chemotherapy regimen in metastatic colorectal adenocarcinoma. MI FOLFOXai™ is included for all metastatic colorectal adenocarcinoma cases.
    Cancer:
    Colorectal Cancer
    Drug:
    Avastin (bevacizumab)
    Confirmatory trial(s)
    TRIBE2
    ,
    NCT02339116
    |
    Clin Cancer Res